Gastroenteritis Clinical Trials

A listing of Gastroenteritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 576 clinical trials
Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children

This is a multi-centre (RDH and ASH), phase IV, double-blind, randomised, placebo-controlled Bayesian adaptive trial of oral NTZ for the treatment of acute gastroenteritis requiring admission to

vaccination
acute gastroenteritis
infectious gastroenteritis
  • 12 views
  • 26 Jan, 2021
  • 2 locations
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 administered intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving chemoradiotherapy for unresectable Stage 3A/3B or post-operative Stage 2B NSCLC, SCLC treatable with chemoradiotherapy.

gc4419
lung cancer
cancer
  • 1 views
  • 06 Apr, 2021
  • 12 locations
Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

The purpose of this study is to investigate the safety and clinical efficacy of HIP2101 in patients with acute or chronic gastritis.

endoscopy
  • 0 views
  • 03 Sep, 2021
  • 1 location
Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)

hysterectomy
metastatic renal cell carcinoma
cancer
  • 7 views
  • 24 Jan, 2021
  • 3 locations
Serum-derived Bovine Immunoglobulin Effect on Mucositis

The purpose of this cancer control clinical research study is to evaluate whether nutritional therapy with Serum-derived bovine immunoglobulin/protein isolate (SBI) might reduce mucositis (a condition caused by cancer treatment involving mouth sores, pain and/or bleeding that may cause difficulty eating), improve nutritional status and lessen the symptoms associated with …

oral ulceration
diarrhea
cancer
  • 0 views
  • 08 Mar, 2021
  • 1 location
Surgical Protocol for Prevention of Mucositis

The main goal of implant therapy is to obtain long-term peri-implant health. Among local risk factors in the etiology of peri-implant diseases the absence of keratinized tissue (KT) around the implant has been reported. In fact, a certain amount of KT width, providing better sensory isolation and, hence, less pain …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide

One of the most common complaints of admission to the emergency room is gastroenteritis. One of the most common complaints in acute gastroenteritis is abdominal pain. The aim of our study is to

  • 0 views
  • 17 Sep, 2021
  • 1 location
A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis

effective in children with viral gastroenteritis. Filtrum-STI (lignin hydrolytic) is a drug with a high absorbing ability, that binds and eliminates toxins, pathogenic microorganisms and viruses

  • 72 views
  • 08 Nov, 2020
  • 2 locations
The Effectiveness of Pleuran in Treatment of Acute Gastroenteritis in Children

Acute gastroenteritis (AGE) is one of the most common causes of children's morbidity and mortality globally. Oral or intravenous rehydration is the only effective treatment in reducing morbidity

  • 0 views
  • 25 Jan, 2021
  • 1 location
Dupilumab in Eosinophilic Gastritis

40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks. Study subjects who complete the 12-week treatment phase, may continue into an open label extension study, where dupilumab will be administered every …

  • 0 views
  • 25 May, 2021
  • 1 location